In this week's report on domestic biotech stocks, シンバイオ製薬 and ネクセラファーマ rose, PRISM BioLab, レナサイエンス and ステムリム fell, and MabGenesis newly listed on the TSE Growth Market.
According to figures compiled by Nikkei Biotechnology ONLINE, 2 stocks rose and 58 fell on 6 November 2026 compared with their closing prices at the end of the previous week. Among the advancing stocks, シンバイオ製薬 gained 54.5% and ネクセラファーマ gained 10.2%, while the decliners were led by PRISM BioLab, down 22.0%, followed by レナサイエンス, down 20.3%, and ステムリム, down 20.1%.
MabGenesis, based in Yokohama, newly listed on the Tokyo Stock Exchange Growth Market on 2 November 2026. The public offering price was ¥830, the opening price was ¥763 and the closing price was ¥696. Its market capitalisation based on the closing price was approximately ¥5.6 billion. The amount raised in connection with the listing was reported to be approximately ¥700 million as of 4 November, with the final amount expected to be determined during November through the over-allotment option and other arrangements.
In Nikkei Biotechnology ONLINE's stock ranking table, the top positions were occupied by シンバイオ製薬 and ネクセラファーマ, while ステムリム, レナサイエンス and PRISM BioLab appeared near the bottom. These movements represent one aspect of weekly share-price trends and are cited as a point of focus for future price movements.